Becton, Dickinson and Company

NYSE (USD): Becton, Dickinson and Company (BDX)

Last Price

227.68

Today's Change

+3.85 (1.72%)

Day's Change

223.51 - 229.31

Trading Volume

2,487,466

Profile
BDX

Exchange:  New York Stock Exchange New York Stock Exchange

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Thomas E. Polen Jr. Mr. Thomas E. Polen Jr.

Full Time Employees:  70,000 70,000

IPO Date:  1973-02-21 1973-02-21

CIK:  0000010795 0000010795

ISIN:  US0758871091 US0758871091

CUSIP:  075887109 075887109

Beta:  0.45 0.45

Last Dividend:  3.89 3.89

Dcf Diff:  -236.78 -236.78

Dcf:  464.46 464.46

Description

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Address

1 Becton Drive,
Franklin Lakes, NJ 07417-1880, US

201 847 6800

http://www.bd.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment